期刊文献+

微粒子酶免疫法测定他可莫司的血药浓度 被引量:2

Determination of whole blood concentration of tacrolimus drug with MEIA
下载PDF
导出
摘要 目的为临床肝移植患者抗移植排斥反应药物的合理应用提供参考。方法采用微粒子酶免疫法(MEIA)对肝移植患者进行他可莫司血药浓度测定,并对结果进行分析。结果为6例肝移植患者检测他可莫司血药浓度77例次,质控结果均在有效范围内。肝移植术后他可莫司全血血药浓度在10-20μg/L范围内的占30.6%。结论为用药安全有效,应对肝移植患者监测FK506血药浓度,实行个体化给药。 Objective To give some information for rationally administrating oral FKS06 to liver wamplant patients in clinical. Methods The whole blood concentration of FK506 on 6 liver transplant patients was determined by mieo - particle enzyme immavnoassy (MEIA), the results and therapeutic effect were studied. Results There were 77 cases in 6 liver transplant patients detemained FK506 concentration, the quality control of MEIA was in effective level, The whole blood with effective level( 10- 20μg/L) were accounted for 30.6 %. Conclusion To be safe and effective for clinical use, it is important for liver transplant patients to monitor whole blood concentrations of FK506 with individualized drug administration.
出处 《宁夏医学杂志》 CAS 2006年第3期168-169,共2页 Ningxia Medical Journal
关键词 他可莫司 血药浓度 微粒子酶免疫法 Tacrolimus Whole Blood Concentration of Drug MEIA
  • 相关文献

参考文献10

  • 1Kino T,Hatanaka H,Hashimoto M,et al.FK506,a novel immunosuppressant isolated from a Streptomyces I Fermenation,isolation and physico-chemicaland biological characteristic[J].Antibit,1987,40(9):1249-1255.
  • 2Taylor J,Alun J,Glenda A,et al.Sensitive specific quantitative analysis of tacrolimus(FK506)in blood by liquid chromatography-electrospray tandem mass spectrometry[J].Clin Chem,1996,42(2):279.
  • 3Przepivrka D,Nash RA,Wingard JR,et al.Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor ma transplantation[J].Blood Marrow Transplant,1999,5(2):94.
  • 4张弋,邢玉,王志玉,王兆青,沈中阳,高仲阳.微粒子酶免疫法监测肝移植术后他克莫司血药浓度[J].中国医院药学杂志,2002,22(12):741-742. 被引量:4
  • 5魏筱华,王共先,秦克旺,刘明珪.他可莫司血药浓度的动态监测及其临床意义[J].实用临床医学(江西),2003,4(6):4-5. 被引量:7
  • 6Mekki O,Lee C.Carrier setal theef fect of food on oral bioavail ability of tarcolimus (FK506)in liver transplant patients[J].Clin Pharmacol Ther,1993,53(2):229-230.
  • 7Sewing K Fr.Pharmacokinetics,dosing principles and blood level monitoring of FK506[J].Transpl Proc,1994,26(6):3267-3269.
  • 8Trimarchi HM,Truong LD,Brennan S,et al.FK506-associated thrombotic microangiopathy:report of two cases and review of the literature[J].Transplantion,1999,67(4):539.
  • 9Yoshida EM,Buczkowski AK,Sirrs SM,et al.Post-transplant diabetic ketoacidosis-apossiple consequence of immunosupression with calcineurin inhibiting agents:a case series[J].Transpl Int,2000,13(1):69.
  • 10丁少波,胡敏燕.他可莫司血药浓度监测[J].中国医院药学杂志,2002,22(3):147-149. 被引量:14

二级参考文献10

  • 1Danovitch GM.Cyclosporin or tacrolimus which agent to choose[J].Nephrol Dial Transplant,1997,12:1566.
  • 2Vincenti F,Laskow DA,Neylan JF,et al.One-year follow up of an open-label trial of FK506 for primary kidney transplantation[J].Transplantation,1996,61:1576.
  • 3Przepivrka D,Nash RA,Wingard JR,et al.Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor ma transplantation[J].rrow Biol Blood Marrow Transplant,1999,5(2):94.
  • 4刘晓琰 施安国 费艳秋 等.免疫抑制剂国内外研究进展[J].上海医院药学,2000,11(3):14-14.
  • 5McMaster P,Mirza DF,Ismail T,et al.Therapeutic drug monitoring of tacrolimus in clinical transplantation[J].Ther Drug Monit,1995,17(3):602.
  • 6Hedayat S,Kershner RP,Su G.Relationship of whole blood FK506 concentrations to rejection and toxicity in liver and kidney transplants[J].J Biopharm Stat,1996,6(2):411.
  • 7Kino T,Hatanake H,Hashimoto H,et al. FK506 a novel immunosuppress antisolated from a Streptomyces I Fermentaion,isolation and physico-chemical and biological characteristic[J].Antibit,1987,40(9) :1 249~1 255.
  • 8Mekki O,Lee C. Carrier setal theef fect of food on oral bioavail ability of tacrolimus(FK506) in liver transplant patients[J].Clin Pharmacol Ther, 1993,53(2): 229~230.
  • 9Sewing K Fr. Pharmacokinetics, dosing principles and blood level monitoring of FK506 [J]. Transpl Proc, 1994,23 (5):3 267~3 269.
  • 10刘永,徐达,王祥慧,唐孝达.他克莫司对肾移植后糖代谢的影响及其控制[J].中华器官移植杂志,2001,22(2):111-112. 被引量:15

共引文献22

同被引文献8

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部